Collaboration will harness the potential of non coding RNAs (ncRNAs) in regenerating heart tissue Ethris will contribute its proprietary SNaP LNP platform for precise ncRNA delivery while Heqet ...
HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in the regeneration of damaged heart tissue Altamira Therapeutics ...
Altamira Therapeutics Ltd. has entered into a collaboration and option agreement with Heqet Therapeutics srl, a spin-out from King’s College London, to utilize the company’s proprietary Oligophore ...
Ethris GmbH and Heqet Therapeutics srl, a company spun out last year from King’s College London, have entered into a collaboration agreement to harness the potential of non-coding RNA (ncRNA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results